Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
[BACKGROUND] While immunotherapy-chemotherapy combinations are approved for programmed death-ligand 1 (PD-L1)-positive advanced triple-negative breast cancer (TNBC), the therapeutic potential of sitra
APA
Liu XY, Sui XY, et al. (2025). Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).. Molecular cancer, 25(1), 15. https://doi.org/10.1186/s12943-025-02505-5
MLA
Liu XY, et al.. "Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).." Molecular cancer, vol. 25, no. 1, 2025, pp. 15.
PMID
41420248
Abstract
[BACKGROUND] While immunotherapy-chemotherapy combinations are approved for programmed death-ligand 1 (PD-L1)-positive advanced triple-negative breast cancer (TNBC), the therapeutic potential of sitravatinib-enhanced immunotherapy remains unexplored.
[METHODS] This multi-cohort, single-arm study enrolled 67 patients with locally recurrent/metastatic TNBC. Cohorts A ( = 21) and B ( = 40) received sitravatinib 70 mg or 100 mg once daily plus tislelizumab, with 38/67 participants having ≥ 1 prior systemic therapy. The primary endpoint was confirmed objective response rate (ORR); secondary endpoints included median progression-free survival (PFS) and safety. Multi-omics analyses including single-cell sequencing and genomic profiling were performed on tumor samples to identify biomarkers linked to treatment response.
[RESULTS] Confirmed ORR was 38.1% (8/21) in Cohort A and 50.0% (20/40) in Cohort B. Median PFS was 8.2 months (Cohort A) and 5.4 months (Cohort B). Notably, 95.3% (41/43) of previously treated patients had PD-L1 combined positive score (CPS) < 10. No grade 4/5 treatment-related adverse events occurred. Biomarker analysis revealed Th17 cell infiltration and TYRO3/AXL/MERTK (TAM) pathway activation correlated with response, while mutations and LSM1 cancer-associated fibroblasts were enriched in non-responders. Post-treatment mutation clearance and increased CD8 T cell proportions predicted improved outcomes.
[CONCLUSIONS] Sitravatinib plus tislelizumab demonstrates promising efficacy and safety as a chemo-free regimen for metastatic TNBC, including PD-L1-negative tumors. Biomarkers such as Th17 cell infiltration, TAM signaling, and mutation dynamics may guide patient selection. These findings support further validation of this combination in PD-L1-negative TNBC and highlight the role of multi-omics in optimizing immunotherapy strategies.
[TRIAL REGISTRATION] ClinicalTrials.gov, NCT04734262.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12943-025-02505-5.
[METHODS] This multi-cohort, single-arm study enrolled 67 patients with locally recurrent/metastatic TNBC. Cohorts A ( = 21) and B ( = 40) received sitravatinib 70 mg or 100 mg once daily plus tislelizumab, with 38/67 participants having ≥ 1 prior systemic therapy. The primary endpoint was confirmed objective response rate (ORR); secondary endpoints included median progression-free survival (PFS) and safety. Multi-omics analyses including single-cell sequencing and genomic profiling were performed on tumor samples to identify biomarkers linked to treatment response.
[RESULTS] Confirmed ORR was 38.1% (8/21) in Cohort A and 50.0% (20/40) in Cohort B. Median PFS was 8.2 months (Cohort A) and 5.4 months (Cohort B). Notably, 95.3% (41/43) of previously treated patients had PD-L1 combined positive score (CPS) < 10. No grade 4/5 treatment-related adverse events occurred. Biomarker analysis revealed Th17 cell infiltration and TYRO3/AXL/MERTK (TAM) pathway activation correlated with response, while mutations and LSM1 cancer-associated fibroblasts were enriched in non-responders. Post-treatment mutation clearance and increased CD8 T cell proportions predicted improved outcomes.
[CONCLUSIONS] Sitravatinib plus tislelizumab demonstrates promising efficacy and safety as a chemo-free regimen for metastatic TNBC, including PD-L1-negative tumors. Biomarkers such as Th17 cell infiltration, TAM signaling, and mutation dynamics may guide patient selection. These findings support further validation of this combination in PD-L1-negative TNBC and highlight the role of multi-omics in optimizing immunotherapy strategies.
[TRIAL REGISTRATION] ClinicalTrials.gov, NCT04734262.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12943-025-02505-5.
같은 제1저자의 인용 많은 논문 (5)
- Chronic social defeat stress accelerates lung cancer progression and induces hippocampal metabolic dysregulation in a duration-optimized comorbid model.
- Post-TARE Survival Outcomes in Hepatocellular Carcinoma: Influence of Pre-TARE Immunotherapy and Targeted Therapy in a Real-World Cohort.
- Development and validation of a nomogram incorporating dietary factors for predicting -negative early gastric cancer risk.
- Peri-operative metabolomic alterations predict post-operative complications and hospital stay in colorectal cancer patients.
- Reactive oxygen species-responsive micelles targeting activated hepatic stellate cells for treating liver fibrosis.